In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.
The approval limits the drug's use to patients who are refractory or intolerant to standard-of-care treatments and contains warnings about the risk of interstitial lung disease.
Radboud University Medical Center researchers developed and validated the single-molecule molecular inversion probe-centered workflow for more efficient BRCA1/2 testing.
The Chinese drug evaluation agency has granted the investigational new drug clinical trial authorization to taletrectinib in NRTK- and ROS1-mutated cancer patients.
